A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
← catalyst calendarNCT06557265 · readout ≤ 254 d
Sponsored by Nkarta, Inc. (industry) · NKTX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
120estimated
Sites
19
Countries
Australia, Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-13 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lupus Nephritis
- Primary Membranous Nephropathy
Interventions
- Drug: NKX019
- Drug: Fludarabine, Cyclophosphamide
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]
measured The first 28 days after the first NKX019 dose
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
measured From the first administration of NKX019 until the last administration of any study treatment + 30 days
Incidence of clinically significant abnormalities in clinical laboratory assessments [Safety and Tolerability]
measured From the first NKX019 dose until the last follow up visit
Permalink · NKTX's whole pipeline · Catalyst calendar · Every registered study · What changed